The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
about
A Chemical Probe for the ATAD2 BromodomainDiscovery and Optimization of a Selective Ligand for the Switch/Sucrose Nonfermenting-Related Bromodomains of Polybromo Protein-1 by the Use of Virtual Screening and Hydration AnalysisSensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibitionBioinformatics and Drug Discovery.Chemical probes targeting epigenetic proteins: Applications beyond oncology.Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology.Polycomb and trithorax opposition in development and disease.Development of novel cellular histone-binding and chromatin-displacement assays for bromodomain drug discoveryStructure-Guided Design of IACS-9571, a Selective High-Affinity Dual TRIM24-BRPF1 Bromodomain Inhibitor.Chromatin Regulators as a Guide for Cancer Treatment ChoiceBRCA1/FANCD2/BRG1-Driven DNA Repair Stabilizes the Differentiation State of Human Mammary Epithelial Cells.Targeting the chromatin remodeling enzyme BRG1 increases the efficacy of chemotherapy drugs in breast cancer cellsMammalian SWI/SNF Enzymes and the Epigenetics of Tumor Cell Metabolic Reprogramming.Impact of Target Warhead and Linkage Vector on Inducing Protein Degradation: Comparison of Bromodomain and Extra-Terminal (BET) Degraders Derived from Triazolodiazepine (JQ1) and Tetrahydroquinoline (I-BET726) BET Inhibitor Scaffolds.Progress in the Development of non-BET Bromodomain Chemical Probes.Multidimensional pooled shRNA screens in human THP-1 cells identify candidate modulators of macrophage polarization.Targeting epigenetic regulators for cancer therapy: modulation of bromodomain proteins, methyltransferases, demethylases, and microRNAs.Epigenomic regulation of oncogenesis by chromatin remodeling.BRG1 regulation by miR-155 in human leukemia and lymphoma cell lines.Marked for death: targeting epigenetic changes in cancer.Bromodomains in Protozoan Parasites: Evolution, Function, and Opportunities for Drug Development.Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology.Bromodomain inhibitors and cancer therapy: From structures to applications.Mammalian SWI/SNF complexes in cancer: emerging therapeutic opportunities.Identification of a Chemical Probe for Family VIII Bromodomains through Optimization of a Fragment HitBRG1 in the Nucleus Accumbens Regulates Cocaine-Seeking Behavior.Synthetic lethal interaction between the tumour suppressor STAG2 and its paralog STAG1.Tumor suppression via inhibition of SWI/SNF complex-dependent NF-κB activationTemporal regulation of chromatin during myoblast differentiation.SMARCA2-regulated host cell factors are required for MxA restriction of influenza A viruses.Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis.CRISPR/Cas9 knockouts reveal genetic interaction between strain-transcendent erythrocyte determinants of Plasmodium falciparum invasion.Target validation: Switching domains.Degradation of the BAF Complex Factor BRD9 by Heterobifunctional Ligands.A New Way Forward in Cancer Drug Discovery: Inhibiting the SWI/SNF Chromatin Remodelling Complex.BRM/SMARCA2-negative clear cell renal cell carcinoma is associated with a high percentage of BRM somatic mutations, deletions and promoter methylation.Chromatin dependencies in cancer and inflammation.The BRG1 ATPase of human SWI/SNF chromatin remodeling enzymes as a driver of cancer.Identifying Small-Molecule Binding Sites for Epigenetic Proteins at Domain-Domain Interfaces.Functional TRIM24 degrader via conjugation of ineffectual bromodomain and VHL ligands.
P2860
Q27727700-21C6B9A4-F571-4FA8-B7F8-E954FDDF8786Q27728041-BBCF02CE-5A64-4AF5-B816-7DC0B9075B6AQ28829718-CABD65DB-F7EA-46C4-B663-AB60A64B04D6Q30395256-E1E46303-927B-41AF-A842-95178C59E7BEQ33751386-ECA572D8-5EB9-4A1F-BC80-FF0D06FA3A26Q33906319-B4C184CB-D44E-4D8A-A0D9-7496BD1B3999Q33920032-443B90E4-E4F8-4B47-9EC1-027E46D021E3Q36082984-5F07BD1D-2900-456D-B4CF-5F252D31C740Q36586506-7DE765F9-7B2A-44EB-9516-294E8AD3E73FQ37075234-F428DE95-7AC8-4B0D-8E46-8CB04E23272CQ37170604-1B16B12F-0F56-4A31-B0A4-A035DD17B7EBQ37317194-578D6235-B1E8-497B-AA71-D94AD5756FBBQ37736010-06AFDE00-D7E1-4129-81E7-C1020FD5F57DQ38673230-03333955-1649-43D3-BD50-1B05B3ADD9BEQ38691377-EA6D3B4F-B4F0-4F10-9657-DA0356438863Q38694268-67FD3684-ED28-438E-A896-B4C7070006D1Q38707876-75371399-FD75-4208-950E-474409EFFD53Q38709544-E173A398-9146-4C01-8473-50A2BE813002Q38714250-922B452A-7876-44C3-9184-BE9A004EABECQ38747872-CF7D00C1-7CEE-4102-BEF8-218AE1786BB7Q38771703-D1459E75-DD39-4557-AD94-D588D199810BQ38837561-598B06B0-A91D-497C-9D08-3CE7F5234AF8Q39027056-081AD771-DBC9-42DF-98C9-6B5AE342775CQ39229171-A3A6A797-36A3-4060-8BA6-3BC16B87CC2EQ39821089-C72A9C4A-07BB-4EB7-B86A-55ACA71E6492Q40648892-F200D13D-FC1B-4F2A-817D-8E81250CE509Q41044192-0D567B30-FF01-4295-85E0-02BD890FAA70Q41718087-D3729468-A2CA-45F5-AAE7-3BFA00AB6B83Q47288294-78286F27-6676-4F54-BFC4-5CFD51621D34Q47546996-D537EB03-F81D-4E19-9ECE-32F1675DE646Q47707307-87D80947-72A7-49BF-B52F-565DEC2785B3Q48014614-841EA936-2826-4A36-AC1D-1C53D8F51C20Q48105865-168E5829-DAE6-42AE-8AD0-B046923CEE6BQ48265414-B5B390EE-DBC3-4F91-B543-9B41951E2443Q48278066-2576AB49-8331-4858-948B-FE84D35BAE31Q48368561-2783D185-68FF-46D1-83C0-E10506472357Q49565575-FF9B1A3B-4F82-45CB-BD4F-97F3400A6AF8Q50640303-A123424F-7E66-433E-9D3A-702B87551DB7Q52631343-264FC847-A696-4A5C-8385-72FAF18DBB68Q52673134-57786139-5D30-47FE-B70D-0456079375DB
P2860
The SMARCA2/4 ATPase Domain Surpasses the Bromodomain as a Drug Target in SWI/SNF-Mutant Cancers: Insights from cDNA Rescue and PFI-3 Inhibitor Studies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@ast
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@en
type
label
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@ast
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@en
prefLabel
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@ast
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@en
P2093
P2860
P1433
P1476
The SMARCA2/4 ATPase Domain Su ...... e and PFI-3 Inhibitor Studies.
@en
P2093
Alessia Petrocchi
Alexei Protopopov
Bhavatarini Vangamudi
Dafydd R Owen
Dominique Verhelle
Elisabetta Leo
Giulio Draetta
Harshad S Mahadeshwar
Jannik N Andersen
Joseph R Marszalek
P2860
P304
P356
10.1158/0008-5472.CAN-14-3798
P407
P577
2015-07-02T00:00:00Z